| Year |
Citation |
Score |
| 2023 |
Sluter MN, Li Q, Yasmen N, Chen Y, Li L, Hou R, Yu Y, Yang CY, Meibohm B, Jiang J. The inducible prostaglandin E synthase (mPGES-1) in neuroinflammatory disorders. Experimental Biology and Medicine (Maywood, N.J.). 15353702231179926. PMID 37515545 DOI: 10.1177/15353702231179926 |
0.345 |
|
| 2023 |
Qiu J, Li Q, Li J, Zhou F, Sang P, Xia Z, Wang W, Wang L, Yu Y, Jiang J. Complementary roles of EP2 and EP4 receptors in malignant glioma. British Journal of Pharmacology. PMID 37232020 DOI: 10.1111/bph.16148 |
0.331 |
|
| 2023 |
Sluter MN, Bhuniya R, Yuan X, Ramaraju A, Chen Y, Yu Y, Parmar KR, Temrikar ZH, Srivastava A, Meibohm B, Jiang J, Yang CY. Novel, Brain-Permeable, Cross-Species Benzothiazole Inhibitors of Microsomal Prostaglandin E Synthase-1 (mPGES-1) Dampen Neuroinflammation and . Acs Pharmacology & Translational Science. 6: 587-599. PMID 37082746 DOI: 10.1021/acsptsci.2c00241 |
0.332 |
|
| 2023 |
Gu M, Yu Y, Xue M, Jiang J, Cai J. The discovery of cyclic γ-AApeptides as the promising ligands targeting EP2. Bioorganic & Medicinal Chemistry Letters. 87: 129255. PMID 36965536 DOI: 10.1016/j.bmcl.2023.129255 |
0.337 |
|
| 2023 |
Chen Y, Nagib MM, Yasmen N, Sluter MN, Littlejohn TL, Yu Y, Jiang J. Neuroinflammatory mediators in acquired epilepsy: an update. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. PMID 36745211 DOI: 10.1007/s00011-023-01700-8 |
0.314 |
|
| 2023 |
Yasmen N, Sluter MN, Li L, Yu Y, Jiang J. Transient inhibition of microsomal prostaglandin E synthase-1 after status epilepticus blunts brain inflammation and is neuroprotective. Molecular Brain. 16: 14. PMID 36694204 DOI: 10.1186/s13041-023-01008-y |
0.368 |
|
| 2022 |
Hou R, Yu Y, Jiang J. Prostaglandin E2 in neuroblastoma: Targeting synthesis or signaling? Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 156: 113966. PMID 36411643 DOI: 10.1016/j.biopha.2022.113966 |
0.349 |
|
| 2022 |
Li L, Chen Y, Sluter MN, Hou R, Hao J, Wu Y, Chen GY, Yu Y, Jiang J. Ablation of Siglec-E augments brain inflammation and ischemic injury. Journal of Neuroinflammation. 19: 191. PMID 35858866 DOI: 10.1186/s12974-022-02556-1 |
0.322 |
|
| 2022 |
Hou R, Yu Y, Sluter MN, Li L, Hao J, Fang J, Yang J, Jiang J. Targeting EP2 receptor with multifaceted mechanisms for high-risk neuroblastoma. Cell Reports. 39: 111000. PMID 35732130 DOI: 10.1016/j.celrep.2022.111000 |
0.366 |
|
| 2022 |
Zhang C, Sajith AM, Xu X, Jiang J, Phillip Bowen J, Kulkarni A, Hao J. Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation. Bioorganic & Medicinal Chemistry. 58: 116645. PMID 35151118 DOI: 10.1016/j.bmc.2022.116645 |
0.355 |
|
| 2021 |
Sluter MN, Hou R, Li L, Yasmen N, Yu Y, Liu J, Jiang J. EP2 Antagonists (2011-2021): A Decade's Journey from Discovery to Therapeutics. Journal of Medicinal Chemistry. PMID 34352171 DOI: 10.1021/acs.jmedchem.1c00816 |
0.394 |
|
| 2020 |
Jiang J, Yu Y. Small molecules targeting cyclooxygenase/prostanoid cascade in experimental brain ischemia: Do they translate? Medicinal Research Reviews. PMID 33094540 DOI: 10.1002/med.21744 |
0.306 |
|
| 2020 |
Li L, Sluter MN, Yu Y, Jiang J. Prostaglandin E receptors as targets for ischemic stroke: Novel evidence and molecular mechanisms of efficacy. Pharmacological Research. 105238. PMID 33053444 DOI: 10.1016/j.phrs.2020.105238 |
0.351 |
|
| 2020 |
Yu Y, Jiang J. COX-2/PGE axis regulates hippocampal BDNF/TrkB signaling via EP2 receptor after prolonged seizures. Epilepsia Open. 5: 418-431. PMID 32913950 DOI: 10.1002/epi4.12409 |
0.321 |
|
| 2020 |
Li L, Yu Y, Hou R, Hao J, Jiang J. Inhibiting the PGE Receptor EP2 Mitigates Excitotoxicity and Ischemic Injury. Acs Pharmacology & Translational Science. 3: 635-643. PMID 32832866 DOI: 10.1021/acsptsci.0c00040 |
0.415 |
|
| 2020 |
Yu Y, Li L, Nguyen DT, Mustafa SM, Moore BM, Jiang J. Inverse Agonism of Cannabinoid Receptor Type 2 Confers Anti-inflammatory and Neuroprotective Effects Following Status Epileptics. Molecular Neurobiology. PMID 32378121 DOI: 10.1007/S12035-020-01923-4 |
0.545 |
|
| 2020 |
Nagib MM, Yu Y, Jiang J. Targeting prostaglandin receptor EP2 for adjunctive treatment of status epilepticus. Pharmacology & Therapeutics. 107504. PMID 32088247 DOI: 10.1016/J.Pharmthera.2020.107504 |
0.563 |
|
| 2019 |
Yu Y, Nguyen DT, Jiang J. G protein-coupled receptors in acquired epilepsy: Druggability and translatability. Progress in Neurobiology. 101682. PMID 31454545 DOI: 10.1016/J.Pneurobio.2019.101682 |
0.428 |
|
| 2019 |
Jiang J, Yu Y, Kinjo E, Du Y, Nguyen H, Dingledine R. Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury. Neuropharmacology. PMID 30763657 DOI: 10.1016/J.Neuropharm.2019.02.011 |
0.765 |
|
| 2019 |
Qiu J, Li Q, Bell KA, Yao X, Du Y, Zhang E, Yu JJ, Yu Y, Shi Z, Jiang J. Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth. British Journal of Pharmacology. PMID 30761522 DOI: 10.1111/Bph.14622 |
0.621 |
|
| 2018 |
Jiang J, Van TM, Ganesh T, Dingledine R. Discovery of 2-Piperidinyl Phenyl Benzamides and Trisubstituted Pyrimidines as Positive Allosteric Modulators of the Prostaglandin Receptor EP2. Acs Chemical Neuroscience. PMID 29292987 DOI: 10.1021/Acschemneuro.7B00486 |
0.779 |
|
| 2017 |
Hartings JA, York J, Carroll CP, Hinzman JM, Mahoney E, Krueger B, Winkler MKL, Major S, Horst V, Jahnke P, Woitzik J, Kola V, Du Y, Hagen M, Jiang J, et al. Subarachnoid blood acutely induces spreading depolarizations and early cortical infarction. Brain : a Journal of Neurology. 140: 2673-2690. PMID 28969382 DOI: 10.1093/Brain/Awx214 |
0.544 |
|
| 2017 |
Kang X, Qiu J, Li Q, Bell KA, Du Y, Jung DW, Lee JY, Hao J, Jiang J. Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype. Scientific Reports. 7: 9459. PMID 28842681 DOI: 10.1038/S41598-017-09528-Z |
0.671 |
|
| 2017 |
Jiang J, Qiu J, Li Q, Shi Z. Prostaglandin E2 Signaling: Alternative Target for Glioblastoma? Trends in Cancer. 3: 75-78. PMID 28718447 DOI: 10.1016/J.Trecan.2016.12.002 |
0.443 |
|
| 2017 |
Qiu J, Du Y, Li Q, Shi Z, Jiang J. Abstract 3114: The role of prostaglandin signaling in human glioblastoma cell activities and growth in vitro and in vivo Cancer Research. 77: 3114-3114. DOI: 10.1158/1538-7445.Am2017-3114 |
0.537 |
|
| 2016 |
Qiu J, Shi Z, Jiang J. Cyclooxygenase-2 in glioblastoma multiforme. Drug Discovery Today. PMID 27693715 DOI: 10.1016/J.Drudis.2016.09.017 |
0.391 |
|
| 2016 |
Dey A, Kang X, Qiu J, Du Y, Jiang J. Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside. Trends in Pharmacological Sciences. PMID 27062228 DOI: 10.1016/J.Tips.2016.03.001 |
0.654 |
|
| 2015 |
Du Y, Kemper T, Qiu J, Jiang J. Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus. Expert Review of Neurotherapeutics. PMID 26689339 DOI: 10.1586/14737175.2016.1134322 |
0.624 |
|
| 2015 |
Du Y, Seibenhener ML, Yan J, Jiang J, Wooten MC. aPKC phosphorylation of HDAC6 results in increased deacetylation activity. Plos One. 10: e0123191. PMID 25860570 DOI: 10.1371/Journal.Pone.0123191 |
0.547 |
|
| 2015 |
Fu Y, Yang MS, Jiang J, Ganesh T, Joe E, Dingledine R. EP2 Receptor Signaling Regulates Microglia Death. Molecular Pharmacology. 88: 161-70. PMID 25715797 DOI: 10.1124/Mol.115.098202 |
0.758 |
|
| 2015 |
Jiang J, Yang MS, Quan Y, Gueorguieva P, Ganesh T, Dingledine R. Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus. Neurobiology of Disease. 76: 126-36. PMID 25600211 DOI: 10.1016/J.Nbd.2014.12.032 |
0.786 |
|
| 2015 |
Varvel NH, Jiang J, Dingledine R. Candidate drug targets for prevention or modification of epilepsy. Annual Review of Pharmacology and Toxicology. 55: 229-47. PMID 25196047 DOI: 10.1146/Annurev-Pharmtox-010814-124607 |
0.765 |
|
| 2014 |
Ganesh T, Jiang J, Dingledine R. Development of second generation EP2 antagonists with high selectivity. European Journal of Medicinal Chemistry. 82: 521-35. PMID 24937185 DOI: 10.1016/J.Ejmech.2014.05.076 |
0.769 |
|
| 2014 |
Ganesh T, Jiang J, Yang MS, Dingledine R. Lead optimization studies of cinnamic amide EP2 antagonists. Journal of Medicinal Chemistry. 57: 4173-84. PMID 24773616 DOI: 10.1021/Jm5000672 |
0.78 |
|
| 2014 |
Rojas A, Jiang J, Ganesh T, Yang MS, Lelutiu N, Gueorguieva P, Dingledine R. Cyclooxygenase-2 in epilepsy. Epilepsia. 55: 17-25. PMID 24446952 DOI: 10.1111/Epi.12461 |
0.75 |
|
| 2013 |
Yan J, Seibenhener ML, Calderilla-Barbosa L, Diaz-Meco MT, Moscat J, Jiang J, Wooten MW, Wooten MC. SQSTM1/p62 interacts with HDAC6 and regulates deacetylase activity. Plos One. 8: e76016. PMID 24086678 DOI: 10.1371/Journal.Pone.0076016 |
0.606 |
|
| 2013 |
Ganesh T, Jiang J, Shashidharamurthy R, Dingledine R. Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists. Acs Medicinal Chemistry Letters. 4: 616-621. PMID 23914286 DOI: 10.1021/Ml400112H |
0.76 |
|
| 2013 |
Jiang J, Dingledine R. Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends in Pharmacological Sciences. 34: 413-23. PMID 23796953 DOI: 10.1016/J.Tips.2013.05.003 |
0.675 |
|
| 2013 |
Seibenhener ML, Zhao T, Du Y, Calderilla-Barbosa L, Yan J, Jiang J, Wooten MW, Wooten MC. Behavioral effects of SQSTM1/p62 overexpression in mice: support for a mitochondrial role in depression and anxiety. Behavioural Brain Research. 248: 94-103. PMID 23591541 DOI: 10.1016/J.Bbr.2013.04.006 |
0.671 |
|
| 2013 |
Quan Y, Jiang J, Dingledine R. EP2 receptor signaling pathways regulate classical activation of microglia. The Journal of Biological Chemistry. 288: 9293-302. PMID 23404506 DOI: 10.1074/Jbc.M113.455816 |
0.738 |
|
| 2013 |
Jiang J, Quan Y, Ganesh T, Pouliot WA, Dudek FE, Dingledine R. Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation. Proceedings of the National Academy of Sciences of the United States of America. 110: 3591-6. PMID 23401547 DOI: 10.1073/Pnas.1218498110 |
0.812 |
|
| 2013 |
Jiang J, Dingledine R. Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. The Journal of Pharmacology and Experimental Therapeutics. 344: 360-7. PMID 23192657 DOI: 10.1124/Jpet.112.200444 |
0.645 |
|
| 2012 |
Jiang J, Ganesh T, Du Y, Quan Y, Serrano G, Qui M, Speigel I, Rojas A, Lelutiu N, Dingledine R. Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proceedings of the National Academy of Sciences of the United States of America. 109: 3149-54. PMID 22323596 DOI: 10.1073/Pnas.1120195109 |
0.808 |
|
| 2010 |
Jiang J, Ganesh T, Du Y, Thepchatri P, Rojas A, Lewis I, Kurtkaya S, Li L, Qui M, Serrano G, Shaw R, Sun A, Dingledine R. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proceedings of the National Academy of Sciences of the United States of America. 107: 2307-12. PMID 20080612 DOI: 10.1073/Pnas.0909310107 |
0.797 |
|
| 2009 |
Jiang J, Parameshwaran K, Seibenhener ML, Kang MG, Suppiramaniam V, Huganir RL, Diaz-Meco MT, Wooten MW. AMPA receptor trafficking and synaptic plasticity require SQSTM1/p62. Hippocampus. 19: 392-406. PMID 19004011 DOI: 10.1002/Hipo.20528 |
0.652 |
|
| 2008 |
Jadhav T, Geetha T, Jiang J, Wooten MW. Identification of a consensus site for TRAF6/p62 polyubiquitination. Biochemical and Biophysical Research Communications. 371: 521-4. PMID 18457658 DOI: 10.1016/J.Bbrc.2008.04.138 |
0.748 |
|
| 2006 |
Jiang J, Suppiramaniam V, Wooten MW. Posttranslational modifications and receptor-associated proteins in AMPA receptor trafficking and synaptic plasticity. Neuro-Signals. 15: 266-82. PMID 17622793 DOI: 10.1159/000105517 |
0.634 |
|
| 2005 |
Geetha T, Jiang J, Wooten MW. Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling. Molecular Cell. 20: 301-12. PMID 16246731 DOI: 10.1016/J.Molcel.2005.09.014 |
0.652 |
|
| Show low-probability matches. |